EGFR and adenocarcinoma: advanced (locally advanced or metastatic) adenocarcinoma EGFR‐mutated (ex19del or L858R mutation) NSCLC, age≥18 years, ECOG 0–1, did not received systemic anticancer therapy for advanced disease; neurologically stable CNS metastases